Kanaph Therapeutics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kanaph Therapeutics develops experimental medicines designed to treat cancer and eye diseases, using human genomic data to identify new drug targets.
It is listed on KOSDAQ, South Korea's tech-focused small-cap exchange, and licenses or co-develops its drug candidates with domestic and international pharmaceutical companies rather than advancing them through late-stage clinical trials itself. Its core business model is early-stage technology transfer, out-licensing pipeline assets to partners and reinvesting the proceeds into new research.
Summary is AI-generated and may contain errors · figures from DART filings
The company has signed technology-transfer and co-development agreements with several named Korean pharmaceutical firms, including Dong-A ST, Oscotec, Yuhan, Lotte Biologics, and GC (Green Cross).
Kanaph Therapeutics in five facts
What does Kanaph Therapeutics do?
Kanaph Therapeutics develops experimental medicines designed to treat cancer and eye diseases, using human genomic data to identify new drug targets.
Where is Kanaph Therapeutics listed and in which sector?
Kanaph Therapeutics (Korean name: 카나프테라퓨틱스) trades under KRX code 0082N0 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Kanaph Therapeutics?
Its market capitalisation was US$110.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kanaph Therapeutics's latest annual revenue and operating profit?
For fiscal year 2025, Kanaph Therapeutics reported revenue of US$4.2M, an operating loss of US$3.2M and a net loss of US$26.8M, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.